SpringerLink
Log in

Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to determine whether post-treatment [18F]fluorodeoxyglucose (FDG) uptake measured as the maximum standardized uptake value (SUVmax) by integrated positron emission tomography (PET)/computed tomography (CT) imaging has prognostic significance in patients with endometrial carcinoma.

Methods

Patients previously treated by primary surgical staging for endometrial carcinoma were imaged with integrated FDG PET/CT during surveillance. PET/CT findings were compared with histological or clinical evaluation, and the relationship between SUVmax on PET/CT and recurrence was examined.

Results

A total of 61 patients were eligible for analysis. Medical records were retrospectively reviewed for clinical data, treatment modalities and outcome. The median duration of follow-up was 31 months (range 6–102 months) post-treatment. SUVmax levels were inversely associated with disease-free survival (DFS). Patients were divided into two groups according to SUVmax (<4.25 versus ≥ 4.25). The Kaplan-Meier survival graph showed a significant difference in DFS between groups [p < 0.001, hazard ratio (HR) 12.959, 95% confidence interval (CI) 3.650–46.011]. In multivariate analyses, post-treatment SUVmax (uncategorized values) evaluated by surveillance PET/CT (p = 0.001, HR 1.199, 95% CI 1.077–1.334) and serous adenocarcinoma histology (p = 0.028, HR 5.594, 95% CI 1.207–25.931) were significantly associated with recurrence.

Conclusion

Post-treatment FDG uptake as measured by SUVmax showed a significant association with recurrence in patients with endometrial carcinoma and may be used as a new useful prognostic marker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035–41.

    Article  CAS  PubMed  Google Scholar 

  3. Podczaski E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323–7.

    Article  CAS  PubMed  Google Scholar 

  4. Carey MS, O’Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995;57:138–44. doi:10.1006/gyno.1995.1115S0090-8258(85)71115-8.

    Article  CAS  PubMed  Google Scholar 

  5. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55–65.

    Article  CAS  PubMed  Google Scholar 

  6. Ayhan A, Tuncer R, Tuncer ZS, Yüce K, Küçükali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases). Int J Gynecol Cancer 1994;4:306–9. doi:10.1046/j.1525-1438.1994.04050306.x.

    Article  PubMed  Google Scholar 

  7. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640–9.

    Article  CAS  PubMed  Google Scholar 

  8. Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 1998;69:192–6. doi:10.1006/gyno.1998.5018S0090-8258(98)95018-1.

    Article  CAS  PubMed  Google Scholar 

  9. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305–32. doi:10.1148/radiol.23120211852312021185.

    Article  PubMed  Google Scholar 

  10. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135–41.

    CAS  PubMed  Google Scholar 

  11. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95.

    CAS  PubMed  Google Scholar 

  12. Chung HH, Kim SK, Kim TH, Lee S, Kang KW, Kim JY, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006;103:165–70. doi:10.1016/j.ygyno.2006.02.016S0090-8258(06)00178-8.

    Article  PubMed  Google Scholar 

  13. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529–34. doi:10.1016/j.ygyno.2006.09.009S0090-8258(06)00716-5.

    Article  PubMed  Google Scholar 

  14. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1132–9. doi:10.1007/s00259-002-0878-2.

    Article  CAS  PubMed  Google Scholar 

  15. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:347–52.

    PubMed  Google Scholar 

  16. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167–71. doi:10.1200/JCO.2004.09.035.

    Article  PubMed  Google Scholar 

  17. Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000;25:905–10.

    Article  CAS  PubMed  Google Scholar 

  18. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, et al. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 2000;3:223–30.

    Article  PubMed  Google Scholar 

  19. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85:53–8.

    Article  CAS  PubMed  Google Scholar 

  20. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34:480–6. doi:10.1007/s00259-006-0260-x.

    Article  PubMed  Google Scholar 

  21. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008;35:1081–8. doi:10.1007/s00259-007-0687-8.

    Article  PubMed  Google Scholar 

  22. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546–51. doi:10.1016/j.ygyno.2004.08.009S0090-8258(04)00627-423.

    Article  PubMed  Google Scholar 

  23. Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007;17:890–6. doi:10.1111/j.1525-1438.2007.00859.x.

    Article  CAS  PubMed  Google Scholar 

  24. Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. Int J Gynecol Cancer 2010;20:110–5. doi: 10.1111/IGC.0b013e3181c3a28800009577-201001000-00018.

    Article  PubMed  Google Scholar 

  25. Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003;17:197–203.

    Article  PubMed  Google Scholar 

  26. Chao A, Chang TC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:36–44. doi:10.1007/s00259-005-1876-y.

    Article  PubMed  Google Scholar 

  27. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36:362–72. doi:10.1007/s00259-008-0956-1.

    Article  PubMed  Google Scholar 

  28. Horiuchi C, Tsukuda M, Taguchi T, Ishiguro Y, Okudera K, Inoue T. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med 2008;22:693–8. doi:10.1007/s12149-008-0162-z.

    Article  CAS  PubMed  Google Scholar 

  29. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771–5. doi:10.2967/jnumed.106.037291.

    Article  PubMed  Google Scholar 

  30. Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–9.

    CAS  PubMed  Google Scholar 

  31. Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47. doi:10.1038/nrc704.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Republic of Korea

    Hyun Hoon Chung, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song & Soon-Beom Kang

  2. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    Keon Wook Kang & June-Key Chung

Authors
  1. Hyun Hoon Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Weon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keon Wook Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noh-Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Sang Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Soon-Beom Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Weon Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, H.H., Kim, J.W., Kang, K.W. et al. Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma. Eur J Nucl Med Mol Imaging 38, 74–80 (2011). https://doi.org/10.1007/s00259-010-1614-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1614-y

Keywords

Search

Navigation